These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 11910970)

  • 41. [Hepatitis C virus genotype 4: epidemiology and treatment].
    Castera L; Morice Y; Grando V; Bon C; Dény P; Roulot D
    Gastroenterol Clin Biol; 2003 Jun; 27(6-7):596-604. PubMed ID: 12910223
    [No Abstract]   [Full Text] [Related]  

  • 42. Treatment of chronic hepatitis C: another therapeutic option.
    Trepo C; Bailly F; Bizollon T
    Nephrol Dial Transplant; 1996; 11 Suppl 4():62-4. PubMed ID: 8918759
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of hepatitis C virus: the first decade.
    Poynard T
    Semin Liver Dis; 2004; 24 Suppl 2():19-24. PubMed ID: 15346242
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Hepatitis C and drug use: epidemiology, screening, natural history and treatment].
    Lucidarme D
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B112-20. PubMed ID: 12180278
    [No Abstract]   [Full Text] [Related]  

  • 45. Hepatitis C recurrence in liver transplant recipients.
    Kizilisik TA; al-Sebayel M; Hammad A; al-Traif I; Ramirez CG; Abdulla A
    Transplant Proc; 1997 Nov; 29(7):2875-7. PubMed ID: 9365599
    [No Abstract]   [Full Text] [Related]  

  • 46. [Clinical guidelines of diagnosis and treatment of hepatitis C].
    Rev Gastroenterol Mex; 2007; 72(2):177-91. PubMed ID: 17966381
    [No Abstract]   [Full Text] [Related]  

  • 47. Incidence, risk factors, and outcome of chronic rejection during antiviral therapy for posttransplant recurrent hepatitis C.
    Fernández I; Ulloa E; Colina F; Abradelo M; Jiménez C; Gimeno A; Meneu JC; Lumbreras C; Solís-Herruzo JA; Moreno E
    Liver Transpl; 2009 Aug; 15(8):948-55. PubMed ID: 19642125
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence.
    Sharma P; Marrero JA; Fontana RJ; Greenson JK; Conjeevaram H; Su GL; Askari F; Sullivan P; Lok AS
    Liver Transpl; 2007 Aug; 13(8):1100-8. PubMed ID: 17377914
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HCV research and anti-HCV drug discovery: toward the next generation.
    Wakita T
    Adv Drug Deliv Rev; 2007 Oct; 59(12):1196-9. PubMed ID: 17905463
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Hepatitis C is curable. Even slightly elevated liver enzymes need further examination].
    Niederau C
    MMW Fortschr Med; 2008 Mar; 150(13):26. PubMed ID: 18522352
    [No Abstract]   [Full Text] [Related]  

  • 51. Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study.
    Cornberg M; Hadem J; Herrmann E; Schuppert F; Schmidt HH; Reiser M; Marschal O; Steffen M; Manns MP; Wedemeyer H
    J Hepatol; 2006 Feb; 44(2):291-301. PubMed ID: 16360972
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A mutational shift from domain III to II in the internal ribosome entry site of hepatitis C virus after interferon-ribavirin therapy.
    Ogata K; Kashiwagi T; Iwahashi J; Hara K; Honda H; Ide T; Kumashiro R; Kohara M; Sata M; Watanabe H; Hamada N
    Arch Virol; 2008; 153(8):1575-9. PubMed ID: 18592133
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hepatitis C virus. Preface.
    Reddy KR; Kaplan DE
    Clin Liver Dis; 2008 Aug; 12(3):xiii-xiv. PubMed ID: 18625424
    [No Abstract]   [Full Text] [Related]  

  • 54. The treatment of hepatitis C.
    Sievert W; Batey RG
    Med J Aust; 1999 Mar; 170(5):200-2. PubMed ID: 10092915
    [No Abstract]   [Full Text] [Related]  

  • 55. Interferon for hepatitis C: where it has been and where it is going.
    Koretz RL
    Immunotherapy; 2013 Jul; 5(7):673-5. PubMed ID: 23829615
    [No Abstract]   [Full Text] [Related]  

  • 56. Hepatitis C: seven years after the discovery of the causative agent.
    Verslype C; Suwandhi W; Clarysse C; Yap SH
    Acta Clin Belg; 1997; 52(1):36-48. PubMed ID: 9085618
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hepatitis C. New treatment helps some, but cure remains elusive.
    Henkel J
    FDA Consum; 1999; 33(2):23-9. PubMed ID: 10214120
    [No Abstract]   [Full Text] [Related]  

  • 58. Interferon therapy for hepatitis C.
    Preston H; Wright TL
    Lancet; 1996 Oct; 348(9033):973-4. PubMed ID: 8855848
    [No Abstract]   [Full Text] [Related]  

  • 59. [How can we improve the system to analyze HCV replication system?].
    Shimotohno K
    Uirusu; 2003 Jun; 53(1):87-91. PubMed ID: 14556507
    [No Abstract]   [Full Text] [Related]  

  • 60. Infectious diseases. Hard-won advances spark excitement about hepatitis C.
    Crabb C
    Science; 2001 Oct; 294(5542):506-7. PubMed ID: 11641482
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.